WATERTOWN

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
Pain, Iron, MF, Safety, Research, Hematology, Porphyria, IRON, EPP, Development, Administration, Ruxolitinib, Patient, Anemia, Society, Quality of life, Bitopertin, PPIX

These data confirmed that bitopertin significantly reduced toxic PPIX in EPP patients and led to reduced phototoxic pain reactions and improved quality of life.

Key Points: 
  • These data confirmed that bitopertin significantly reduced toxic PPIX in EPP patients and led to reduced phototoxic pain reactions and improved quality of life.
  • Research and Development Expenses: R&D expenses were $23.7 million for the quarter ended March 31, 2024, as compared to $20.2 million for the quarter ended March 31, 2023.
  • General and Administrative Expenses: G&A expenses were $7.8 million for the quarter ended March 31, 2024, as compared to $4.9 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $26.9 million for the quarter ended March 31, 2024, as compared to $22.8 million for the quarter ended March 31, 2023.

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, May 8, 2024
Science, FDA, AMD, Investment, DOI, Safety, OIS, Stuart, Florida, Food, Research, Cleveland Clinic, Growth, FACS, KOL, Therapy, Thomas Jefferson University, Eye, Wills Eye Hospital, Marketing, DME, Clinical trial, Associate, Diabetic retinopathy, ARVO, Plasma, Uveitis, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Key Points: 
  • The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data in the third quarter of 2024.
  • EyePoint plans to host an R&D Day on June 26, 2024 in New York City.
  • Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million.
  • Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million versus $29.2 million in the prior year period.

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, May 8, 2024
Sale, Congress, Dexamethasone, Merck Group, Research and development, Security (finance), Colorectal cancer, Hematology, Research, Therapy, Finance, CRC, ESMO, ATM, Administration, Roche, Public expenditure, BRAF, Completeness, Cancer, Patient, NHL, Melanoma, AACR, Clinical trial, Merck, CCCC, G&A, Lung cancer, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the first quarter of 2024 was $3.0 million, compared to $3.8 million for the first quarter of 2023.
  • General and Administrative (G&A) Expense: G&A expense, net of a one-time $0.5 million restructuring charge, was $10.3 million for the first quarter of 2024.
  • Net Loss and Net Loss per Share: Net loss for the first quarter of 2024 was $28.4 million, compared to $34.8 million for the first quarter of 2023.
  • Net loss per share for the first quarter of 2024 was $0.41 compared to $0.71 for the first quarter of 2023.

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Retrieved on: 
Wednesday, May 8, 2024
Bank of America, News, Conference, BofA Securities, TPD, Therapy

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Key Points: 
  • WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
    BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; and
    TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m.
  • ET.
  • Live webcasts of the presentations will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • Replays of the webcasts will be archived and available following the events.

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 7, 2024
FDA, PAM, Inflammation, Safety, DSM-IV codes, NLRP3, Research, IND, Aggression, M4, SAD, Patient, Toxicology, Therapy, Pharmaceutical industry

WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • The Company expects to initiate a Phase 2 clinical trial in BPD in the second quarter of 2024.
  • Neumora expects to initiate a Phase 1b study in Alzheimer's disease agitation in the second quarter of 2024, with data from that study anticipated in 2025.
  • Neumora is working with the FDA to evaluate the potential to resolve the clinical hold and will provide an update when available.
  • Cash Position: As of March 31, 2024, Neumora had cash, cash equivalents and marketable securities of $423.0 million.

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Retrieved on: 
Monday, May 6, 2024
AMD, FDA, Safety, Retinal vasculitis, Conference call, Conference, Arm, Disease, TKI, Therapy, Patient, DME, Diabetic retinopathy, Endophthalmitis, Retina, Anti-VEGF, Pharmaceutical industry

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The data demonstrated that DURAVYU has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint. The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data.

Key Points: 
  • “The objective of the PAVIA trial was, for the first time, to evaluate DURAVYU as a potential treatment in a non-proliferative diabetic patient population,” said Jay Duker, M.D., Chief Executive Officer of EyePoint Pharmaceuticals.
  • I would like to thank the patients, the investigators and their site staff who participated in the PAVIA trial.
  • PAVIA is a 12-month, randomized, controlled Phase 2 clinical trial of DURAVYU in patients with moderately-severe to severe NPDR.
  • A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com .

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Retrieved on: 
Monday, May 6, 2024
Sinusitis, CRS, LYRA, Network congestion, Data, Workforce, ITT, Therapy, Nosebleed

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment for chronic rhinosinusitis (CRS).

Key Points: 
  • WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS).
  • ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment for chronic rhinosinusitis (CRS).
  • “We are surprised and disappointed by the ENLIGHTEN 1 topline results,” said Maria Palasis, Ph.D., President and Chief Executive Officer, Lyra Therapeutics.
  • The ENLIGHTEN 1 trial is ongoing and data from the 52-week extension phase are expected in Q4 2024.

Neumora Therapeutics to Participate in Upcoming Conferences in May

Retrieved on: 
Monday, May 6, 2024
Therapy, Conference

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May:

Key Points: 
  • WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May:
    BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.
  • 2024 RBC Capital Markets Global Healthcare Conference: Members of management will participate in a fireside chat on Wednesday, May 15, 2024, at 9:00 AM ET in New York, NY.
  • A live webcast of each event will be available on the events and presentations section of the Company’s website at www.neumoratx.com .
  • A replay of the webcasts will be available following the completion of the event and will be archived for up to 30 days.

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
Cancer, Irritable bowel syndrome, Phenotype, IL-2, Food, Research, Pembrolizumab, Colitis, Immunotherapy, PacWest Bancorp, Tumor microenvironment, Defecation, ASCO, Therapy, Immunology, Patient, Society, BPR, Poster, Clinical trial, Annual general meeting, Non-Hodgkin lymphoma, Food and Drug Administration, DSM-IV codes, Pharmaceutical industry

“Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.

Key Points: 
  • “Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.
  • Financial Results for the First Quarter of 2024:
    Cash position: As of March 31, 2024, cash and cash equivalents were $139.2 million, compared to $134.3 million as of December 31, 2023.
  • General and administrative expenses: General and administrative expenses were $5.0 million for each of the first quarters of 2024 and 2023.
  • Net loss: Net loss was $16.2 million for the first quarter of 2024, compared to $12.0 million for the same period in 2023.

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Retrieved on: 
Thursday, April 25, 2024
News, Webcast, TPD, International, Therapy

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m.

Key Points: 
  • WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m.
  • To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.
  • A live webcast of the Company’s conference call will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • A replay of the webcast will be archived and available following the event.